Global Antibiotic Research and Development Partnership and University of Liverpool join forces to fight antimicrobial resistance

Global Antibiotic Research and Development Partnership and University of Liverpool join forces to fight antimicrobial resistance

(IN BRIEF) The University of Liverpool and the Global Antibiotic Research and Development Partnership (GARDP) have signed a Memorandum of Understanding to collaborate on new projects to address antimicrobial resistance (AMR). They have been working together since 2018 to advance new treatment options for newborns with sepsis. The joint research has laid the groundwork for GARDP’s upcoming global clinical trial on neonatal sepsis. GARDP and the University of Liverpool have also joined forces to share their expertise with the wider community of researchers who work on AMR.

(PRESS RELEASE) LIVERPOOL, 9-Mar-2023 — /EuropaWire/ —  University of Liverpool, a public research university, and the Global Antibiotic Research and Development Partnership (GARDP) have joined forces once again to tackle antimicrobial resistance (AMR) through a new collaborative effort. Both organizations have signed a Memorandum of Understanding to initiate new projects aimed at addressing AMR for the public’s benefit.

Since 2018, the University of Liverpool and GARDP have worked together to advance new treatments for newborns with sepsis. Their research has already paved the way for GARDP’s upcoming global clinical trial on neonatal sepsis, which will compare the safety and effectiveness of new antibiotic combinations against commonly used regimens to treat babies with sepsis.

“The University of Liverpool is a leader in infectious disease research and a key partner in GARDP’s work on children’s antibiotics,” said Seamus O’Brien, R&D Director at GARDP. “This agreement paves the way for more successful collaboration across our portfolio in years to come. We look forward to continuing to work together on solutions for all populations that are especially vulnerable to drug-resistant infections.”

Professor William Hope, Dame Sally Davies Chair of AMR Research at the University of Liverpool said, “The University of Liverpool has enjoyed a highly fruitful and effective collaboration with GARDP to advance a collective vision to minimise the impact of antimicrobial resistance on human health. Effectively addressing global challenges such as AMR can only be achieved with strong partnership and interdisciplinary problem-solving. We anticipate further successes and look forward to this very much.”

Aside from their joint research, GARDP and the University of Liverpool are committed to sharing their expertise with the broader AMR research community. University of Liverpool academics have already presented their work in GARDP’s online platform REVIVE and at the Antimicrobial Chemotherapy Conference co-hosted by GARDP.

GARDP is a Swiss not-for-profit organization that develops new treatments for drug-resistant infections that pose a severe threat to global health.

Media contact:

Jennifer Morgan
Media Relations Manager – Health and Life Sciences
T: +44 (0)7775 547589
E: J.L.Morgan@liverpool.ac.uk

SOURCE: University of Liverpool

MORE ON UNIVERSITY OF LIVERPOOL, ETC.:

Follow EuropaWire on Google News
EDITOR'S PICK:

Comments are closed.